Ginkgo Bio Rg-A
DNA
USD
STOCK MARKET:
NYX
Closed
 
...
Large gap with delayed quotes
Last quote
07/01/2025 - 22:15:00
Bid
07/01/2025 - 21:59:59
Bid
Volume
Ask
07/01/2025 - 21:59:59
Ask
Volume
11.36
+0.11 ( +0.98% )
11.35
15,900
11.39
3,300
More information
Analysis by TheScreener
01.07.2025
Evaluation Slightly negative  
Interest Strong  
Sensibility High  
Analysis date: 01.07.2025
Global Evaluation
  Slightly negative
The stock is classified in the slightly negative zone since 13.06.2025.
Interest
  Strong
Three stars since 17.06.2025.
Earnings Rev Trend
  Positive
 
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 17.06.2025 at a price of 8.55.
Evaluation
  Strongly overvalued
 
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
  Positive
 
The forty day technical trend is positive since 06.06.2025.
4wk Rel Perf
  54.91%
 
The four-week dividend-adjusted overperformance versus SP500 is 54.91%.
Sensibility
  High
High, no change over 1 year.
Bear Market Factor
  High
On average, the stock has a tendency to amplify the drops in the index by 2.69%.
Bad News Factor
  Low
When the stock's pressure is specific, the market sanction on average is 8.38%.
Mkt Cap in $bn
  0.66
With a market capitalization <$2bn, GINKGO BIOWORKS HOLDINGS A is considered a small-cap stock.
G/PE Ratio
  4.97
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).
LT P/E
  -2.45
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
  12.19%
The annualized growth estimate is for the current year to 2026.
Avg. Nb analysts
  3
Over the last seven weeks, an average of 3 analysts provided earnings per share estimates.
Dividend Yield
  0.00%
The company is not paying a dividend.
Beta
  232
For 1% of index variation, the stock varies on average by 2.32%.
Correlation
  0.40
40.14% of stock movements are explained by index variations.
Value at Risk
  10.79
The value at risk is estimated at USD 10.79. The risk is therefore 95.00%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
  21.12.2021